

New TAP Compound in Development at Immunogen



- huMv9-6-DM1: CD33-positive tumors (AML)

Appendix A.

Therapeutic Window for My9-6-DM1

My9-6-DM1, i.v., d x 5

Appendix A



Days after Tumor Inoculation

Days after Tumor Inoculation

R. J. Lutz et al. Proceedings of AACR 43, 912 (2002). Abstract 4518

Dose refers to amount of conjugated calicheamicin

Anti-CD133/CD1

Antitumor efficacy of MyD-CD1





Fig. 1. Antitumor efficacy of MyD-CD1. Mice were injected with 1×10^5 cells of leukemia tumor cells. Mice were sacrificed at 28 days post-tumor injection. Tumor volume was measured at 0, 7, 14, 21, and 28 days post-tumor injection. * indicates significant difference ($p < 0.05$) between control and MyD-CD1 groups.

MyD-CD1 induces long-term control of tumor bearing leukemia, B1 and myelogenous leukemia tumor cells.

Therapeutic efficacy was significantly improved in mice bearing leukemia tumor cells.

MyD-CD1 induces long-term control of tumor bearing leukemia, B1 and myelogenous leukemia tumor cells. Mice were injected with 1×10^5 cells of leukemia tumor cells. Mice were sacrificed at 28 days post-tumor injection. Tumor volume was measured at 0, 7, 14, 21, and 28 days post-tumor injection. * indicates significant difference ($p < 0.05$) between control and MyD-CD1 groups.

MATERIALS

The efficacy of MyD-CD1 in inducing long-term control of tumor bearing leukemia, B1 and myelogenous leukemia tumor cells was evaluated in mice bearing leukemia tumor cells.

MyD-CD1 induces long-term control of tumor bearing leukemia, B1 and myelogenous leukemia tumor cells.



Fig. 3. Antitumor efficacy of MyD-CD1. Mice were injected with 1×10^5 cells of leukemia tumor cells. Mice were sacrificed at 28 days post-tumor injection. Tumor volume was measured at 0, 7, 14, 21, and 28 days post-tumor injection. * indicates significant difference ($p < 0.05$) between control and MyD-CD1 groups.

Therapeutic efficacy was significantly improved in mice bearing leukemia tumor cells.

Anti-CD133/CD1

Antitumor efficacy of MyD-CD1




Fig. 2. Antitumor efficacy of MyD-CD1. Mice were injected with 1×10^5 cells of leukemia tumor cells. Mice were sacrificed at 28 days post-tumor injection. Tumor volume was measured at 0, 7, 14, 21, and 28 days post-tumor injection. * indicates significant difference ($p < 0.05$) between control and MyD-CD1 groups.

MyD-CD1 induces long-term control of tumor bearing leukemia, B1 and myelogenous leukemia tumor cells.

Therapeutic efficacy was significantly improved in mice bearing leukemia tumor cells.





Fig. 3. Antitumor efficacy of MyD-CD1. Mice were injected with 1×10^5 cells of leukemia tumor cells. Mice were sacrificed at 28 days post-tumor injection. Tumor volume was measured at 0, 7, 14, 21, and 28 days post-tumor injection. * indicates significant difference ($p < 0.05$) between control and MyD-CD1 groups.

MyD-CD1 induces long-term control of tumor bearing leukemia, B1 and myelogenous leukemia tumor cells.

Therapeutic efficacy was significantly improved in mice bearing leukemia tumor cells.



MyD-CD1 induces long-term control of tumor bearing leukemia, B1 and myelogenous leukemia tumor cells.

Therapeutic efficacy was significantly improved in mice bearing leukemia tumor cells.

These data suggest the continued development of MyD-CD1 for the treatment of B1.

Examples of TAPs currently in development

Appendix C:

- | | |
|-------------------------|------------|
| • SB-408075/ huC242-DM1 | colorectal |
| • huN901-DM1 | lung |
| • My9-6-DM1 | AML |
| • Herceptin-DM1 | breast |

IMMUNOGEN, INC.

My9-6-DM1 TAP

Biological Marker: CD33

For the treatment of acute myeloid leukemia (AML)

In preclinical development


Humanization of My9-6 using patented ImmunoGen technology

IMMUNOGEN, INC.

Appendix C

My9-6-DM1 cures HL-60 tumor xenografts

Appendix C



IMMUNOGEN, INC.

TAP Technology Platform: Summary

Appendix C.

- Widely applicable for cancer huMAbs
- Generates product candidates with superior preclinical efficacy
- Incorporated into two product candidates currently in clinical trials:
 - SB-408075/ huc242-DM1 (GlaxoSmithKline)
 - huN901-DM1 (Immunogen/ British Biotech)
- TAPs under preclinical development include Herceptin®-DM1 (Genentech), MY3-6-DM1 (Immunogen)
- Agreements with Genentech, Abgenix, Millennium, and others to develop additional huMAb-DM1 TAPs
- Additional Immunogen TAPs are under development

IMMUNOGEN, INC.